# Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

> **NCT02792699** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 311 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** ABP 798
- **DRUG:** Rituximab (US)
- **DRUG:** Rituximab (EU)

## Key facts

- **NCT ID:** NCT02792699
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-17
- **Primary completion:** 2018-10-08
- **Final completion:** 2018-10-08
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02792699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02792699, "Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02792699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*